PTGS2 and exocrine pancreatic carcinoma: Bergmann et al. identified druggable genomic targets (L1CAM, cyclooxygenase 2, epidermal growth factor receptor) in a high proportion of undifferentiated pancreatic carcinomas, including UCOGC [55].